Current
21.1×
5-Year Average
56.0×
All-Time High
715.3×
All-Time Low
7.6×
P/FCF Ratio daily chart for Boston Scientific (BSX)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Boston Scientific (BSX) from 2001 to 2025
| 2025 | $141.38B | $3.63B | 39.0× | -15.0× | |
| 2024 | $131.68B | $2.44B | 54.0× | +4.3× | |
| 2023 | $84.71B | $1.70B | 49.7× | -22.5× | |
| 2022 | $66.29B | $918.00M | 72.2× | +26.2× | |
| 2021 | $60.54B | $1.32B | 46.0× | -5.2× | |
| 2020 | $51.33B | $1.00B | 51.2× | +0.3× | |
| 2019 | $63.05B | $1.24B | 50.9× | — | |
| 2018 | $48.92B | −$154.00M | — | — | |
| 2017 | $34.04B | $1.21B | 28.2× | -21.2× | |
| 2016 | $29.46B | $596.00M | 49.4× | -18.6× | |
| 2015 | $23.87B | $351.00M | 68.0× | +50.6× | |
| 2014 | $17.58B | $1.01B | 17.4× | -1.4× | |
| 2013 | $15.98B | $850.00M | 18.8× | +11.1× | |
| 2012 | $7.83B | $1.02B | 7.7× | -3.3× | |
| 2011 | $7.72B | $704.00M | 11.0× | -234.9× | |
| 2010 | $11.56B | $47.00M | 245.9× | +217.1× | |
| 2009 | $13.60B | $473.00M | 28.7× | +15.1× | |
| 2008 | $11.62B | $854.00M | 13.6× | -16.8× | |
| 2007 | $17.38B | $571.00M | 30.4× | +13.6× | |
| 2006 | $25.26B | $1.50B | 16.8× | -18.3× | |
| 2005 | $20.33B | $579.00M | 35.1× | +15.8× | |
| 2004 | $29.60B | $1.53B | 19.3× | -32.4× | |
| 2003 | $31.01B | $599.00M | 51.8× | +24.2× | |
| 2002 | $17.19B | $624.00M | 27.5× | +0.7× | |
| 2001 | $9.89B | $369.00M | 26.8× | — |
- 202539.0×
- 202454.0×
- 202349.7×
- 202272.2×
- 202146.0×
- 202051.2×
- 201950.9×
- 2018—
- 201728.2×
- 201649.4×
- 201568.0×
- 201417.4×
- 201318.8×
- 20127.7×
- 201111.0×
- 2010245.9×
- 200928.7×
- 200813.6×
- 200730.4×
- 200616.8×
- 200535.1×
- 200419.3×
- 200351.8×
- 200227.5×
- 200126.8×
About P/FCF Ratio at Boston Scientific (BSX)
Boston Scientific (BSX) P/FCF ratio is 21.1× as of June 5, 2026. The 5-year average is 56.0×. The sector median currently stands at 19.8×. The current ratio is at the 0th percentile of its own 10-year history.
Boston Scientific (BSX) historical P/FCF ratio has ranged from a low of 7.6× (2012) to a high of 715.3× (2019) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Boston Scientific P/FCF Ratio by Year
Boston Scientific P/FCF Ratio 2025: 39.0×
Boston Scientific (BSX) P/FCF ratio in 2025 was 39.0×, contracted from 54.0× the prior year.
Boston Scientific P/FCF Ratio 2024: 54.0×
Boston Scientific (BSX) P/FCF ratio in 2024 was 54.0×, expanded from 49.7× the prior year.
Boston Scientific P/FCF Ratio 2023: 49.7×
Boston Scientific (BSX) P/FCF ratio in 2023 was 49.7×, contracted from 72.2× the prior year.
Boston Scientific P/FCF Ratio 2022: 72.2×
Boston Scientific (BSX) P/FCF ratio in 2022 was 72.2×, expanded from 46.0× the prior year.
Boston Scientific P/FCF Ratio 2021: 46.0×
Boston Scientific (BSX) P/FCF ratio in 2021 was 46.0×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Boston Scientific (BSX), ranked by P/FCF ratio.
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.7× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 17.8×
- 16.9×
- 16.7×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Boston Scientific (BSX) Key Financials
Charts, filings, and peer comparison for every metric